Skip to main content
Equibles
PBLS logo

PBLS · Parabilis Medicines, Inc.

Track PBLS — free

Use PBLS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PBLS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$37.07 +1.40 (+3.92%) At close · Aug 14
Market Cap
$4.58B
Shares
123.53M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$37.07 Open$35.67 Day$34.78–37.99 Available close range$25.01–37.41 Avg vol 30d405K Short int5.1M · 4.1% float · 12.8d Short vol68% DataJun 2026–Aug 2026 Filing10-Q · Aug 13

The closing range uses available history since Jun 10, 2026; less than a full year is stored.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Buy
50 / 200-day cross No cross
RSI (14) 63
neutral
MACD trend Positive
52-week position 97%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+79 funds added
Insider flow Accumulating
Net +$441.4M over 90 days · 0% sells
Short interest Rising
4.14% of float · ▲ +29.4% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
79 holders — 13F breadth
Squeeze score 78
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 72%
annualized · 1-yr
Max drawdown −21%
past year
ATR 6.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 2
50 / 200-day cross
No cross Neutral
RSI (14)
63 Neutral
MACD trend
Positive Bullish
52-week position
97% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+79 funds added
Insider flow Accumulating
Net +$441.4M over 90 days · 0% sells
Short interest Rising
4.14% of float · ▲ +29.4% MoM · 12.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
79 holders — 13F breadth
Price context
position in its available closing range
Range low $25 Now $37 · 97% Range high $37

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents, and marketable securities $1.1B as of June 30, 2026 —
DCR in Non-CRC Patients with Tumors of Low Genomic Complexity 87% as of Feb 16, 2026 —
Efficacy evaluable patients with tumors of low genomic complexity 39 as of Feb 16, 2026 —
IPO proceeds $770.5M completed in June 2026 —
RECIST 1.1 responses in Non-CRC Patients with Tumors of Low Genomic Complexity 20 as of Feb 16, 2026 —
Upfront and equity investment from Regeneron collaboration $125M deal economics —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PBLS
Parabilis Medicines, Inc.
this stock
$4.58B — — — 4.1%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
79
% held
78.8%
Net QoQ
+97.4M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
5.1M
Days to cover
12.8d
Change
+1.2M sh
View
Short Volume
Short vol %
68%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
2.0K
Value
$58.6K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
49.8%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$441.4M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
3
View
Exempt Offerings
Offering
$178.0M
Filed
Dec 2, 2022
View

Performance

5D 20D 120D MTD YTD
PBLS +6.0% +25.5% — +9.1% —
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY +5.6% +21.0% — +5.2% —
Key facts CIK 1657677 CUSIP 698955101 13F (30d) 81 filings 80 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)